[Determination of lipoproteins defined following their apolipoprotein composition for the prediction of cardiovascular risk].
Immunological methods permit separation and measurement of lipoprotein concentrations in terms of their apolipoprotein composition. We have elaborated two different methods to measure lipoprotein particles in plasma. The first is a selective bi-site Elisa procedure and the second a differential electroimmunoassay. Lp A-I plays an essential role in reverse cholesterol transport. We have shown that Lp A-I is an anti-risk marker of atherosclerosis. Its concentration is higher in females than in males, it is decreased in patients with coronary heart disease and in their kindreds and in populations with a high cardiovascular risk. This fraction is increased in octogenarians. In pharmacological terms, HMG CoA reductase inhibitors increase Lp A-I and Lp A-I:A-II while fenofibrate decreases Lp A-I and increases Lp A-I:A-II. These studies demonstrate that the measurement of lipoprotein concentrations according to their apolipoprotein composition can reveal lipoprotein fractions that have precise metabolic roles with epidemiological and pathophysiological implications.
Duriez
P
P
Serlia et Inserm U325, institut Pasteur, Lille, France.
Fruchart
J C
JC
D016632:Apolipoprotein A-I / Q000032:analysis*; D016633:Apolipoprotein A-II / Q000032:analysis*; D001161:Arteriosclerosis / Q000453:epidemiology*; D004563:Electrochemistry; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007118:Immunoassay; D017270:Lipoprotein(a) / Q000737:chemistry* / Q000378:metabolism; D008297:Male; D011379:Prognosis; D012307:Risk Factors; D012737:Sex Factors
D016632:Apolipoprotein A-I; D016633:Apolipoprotein A-II; D017270:Lipoprotein(a)
Dosage des lipoprotéines définies selon leur composition en apolipoprotéines en vue de la prédiction du risque cardiovasculaire.